Indaptus Therapeutics is trading 11.59% down at $1.22, apparently due to profit-taking and broader biotech-sector weakness rather than a new company-specific announcement.
- Shares rose 46.81% to $1.38 on August 20, 2026.
- The latest reported update was the company’s August 13, 2026 second-quarter release.
- That source identifies no August 21 announcement or specific catalyst for the decline.